Key clinical point: Zoledronic acid plus good oral hygiene may prevent development of osteonecrosis of the jaw.

Major finding: Oral adverse events were significantly more common in the placebo group, compared with the zoledronic acid group (20% vs. 14%; P = .04, respectively), as were symptomatic periodontal disease (12% vs. 5%; P = .002).

Study details: Retrospective analysis of 542 men and women with osteoporosis in the randomized ZONE trial who received zoledronic acid (n = 258) or placebo (n = 284) once yearly for 2 years by IV infusion while maintaining good oral health.

Disclosures: The study was funded by Asahi-Kasei Pharma. The investigators reported employment with or receiving consulting fees from numerous pharmaceutical companies.